Luvox CR

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Luvox CR

What is Luvox CR?

Luvox CR is an extended-release formulation of fluvoxamine maleate, a medication belonging to the class of drugs known as selective serotonin reuptake inhibitors (SSRIs). Unlike immediate-release versions, the controlled-release (CR) technology is designed to release the medication gradually into the bloodstream over an extended period.

Mechanism of Action

The active ingredient, fluvoxamine, works by affecting neurotransmitters in the brain, specifically serotonin. Serotonin is a chemical messenger involved in regulating mood, anxiety, and sleep. By inhibiting the reabsorption (reuptake) of serotonin by nerve cells, the medication increases the availability of this neurotransmitter in the synaptic gap between neurons, which helps to enhance nerve cell communication.

Primary Uses

Luvox CR is primarily utilized for the management of obsessive-compulsive disorder (OCD). OCD is characterized by persistent, unwanted thoughts (obsessions) and the urge to perform repetitive behaviors (compulsions). The medication is intended to help reduce the frequency and intensity of these symptoms, thereby improving daily functioning and quality of life.

In certain clinical contexts, healthcare providers may also utilize this formulation for the treatment of social anxiety disorder (SAD), also known as social phobia. This condition involves an intense fear of social situations or performance settings where an individual may feel scrutinized by others.

Key Characteristics

  • Extended-Release Delivery: The "CR" designation indicates a controlled-release delivery system, which typically allows for once-daily administration.
  • Selective Action: As an SSRI, it is designed to specifically target the serotonin system with minimal impact on other neurotransmitters like norepinephrine or dopamine.
  • Therapeutic Intent: The goal of treatment is the long-term stabilization of symptoms associated with anxiety and obsessive-compulsive cycles.

Regulatory References

  1. Fluvoxamine LiverTox entry

What side effects are possible with Luvox CR?

Possible side effects and safety information

The official safety profile for Luvox CR (fluvoxamine) is organized according to the frequency and physiological system affected, as mandated by regulatory authorities. Adverse reactions are classified using terms like Very Common, Common, and Uncommon/Rare.

Very Common adverse reactions, which are those most frequently reported in official labeling, include nausea, insomnia or somnolence, headache, asthenia, and dry mouth. Common effects often include sexual dysfunction (e.g., decreased libido or ejaculation failure), tachycardia, and sweating.

The regulatory safety information highlights several Serious Adverse Reactions. These include the risk of Serotonin Syndrome, seizures/convulsions, and documented cases of Hyponatraemia (low sodium). Specific attention is paid to the documented risk of suicidal ideation and behavior in children, adolescents, and young adults, particularly early in treatment or following dose changes.

Safety characteristics are also defined by Population-Specific Considerations. Official labeling notes increased caution for older adults due to higher risks for events such as bleeding and hyponatraemia. Use is contraindicated in combination with Monoamine Oxidase Inhibitors (MAOIs). Furthermore, caution is advised for individuals with a history of mania or epilepsy.

These classifications reflect how government regulatory documents organize and communicate the medicine's safety profile, serving as the foundational reference for safety characteristics.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Luvox CR (fluvoxamine maleate) overdose is based strictly on documentation from government regulatory authorities and prescribing information.

Documented Overdose Manifestations

Official labeling documents symptoms ranging from common effects to severe outcomes. Manifestations can include:

  • Gastrointestinal: Nausea, Vomiting, and Diarrhea.
  • Central Nervous System (CNS): Somnolence (Drowsiness), Dizziness, Tremor, Convulsion (Seizures), and Coma.
  • Cardiovascular: Tachycardia (Fast Heart Rate).

Serious Outcomes and Emergency Action

Serious complications reported in association with overdose include cardiac events, liver function abnormalities, and the risk of Serotonin Syndrome. Due to the potential for life-threatening outcomes, immediate medical attention is required for any suspected overdose.

Regulators emphasize seeking urgent medical help or contacting emergency services immediately if the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened (coma).

Management and Monitoring

There is no specific antidote for fluvoxamine overdose documented in official regulatory labeling. Treatment is entirely focused on symptomatic and supportive care. Management steps described include establishing and maintaining an airway, ensuring adequate oxygenation and ventilation, and considering procedures such as gastric lavage or activated charcoal. Continuous cardiac monitoring is officially recommended for observation.

Therapeutic Uses of Luvox CR

What Luvox CR Treats: Main Uses and Benefits

The primary therapeutic role of Luvox CR is to provide symptomatic support in certain chronic mental health conditions where symptoms interfere with daily functioning. The focus is on easing the overall burden of symptoms to help patients cope more steadily.

Luvox CR is commonly applied in the long-term management of conditions involving intrusive thoughts and high anxiety, including Obsessive-Compulsive Disorder (OCD) and Social Anxiety Disorder. It is relevant when symptoms create noticeable interference with daily stability. The medication specifically helps address symptom groups like intrusive, unwanted thoughts (obsessions) and the resulting urge to perform ritualized, repetitive behaviors (compulsions), as well as pervasive fear of social interaction or performance.

“Luvox CR is applied in contexts where additional support for symptom management is needed to help ease pervasive fear and avoidance patterns.”

The controlled-release formulation is designed to support consistent symptom stability across the full duration of the day, assisting in the long-term management of persistent and recurrent affective symptoms. Luvox CR may help improve day-to-day comfort and supports patients in social and occupational settings during phases where chronic apprehension or self-consciousness is particularly challenging.

Quick Fact: Relief for Obsessive and Anxious Symptoms
This medication is commonly used to help manage the intensity of unwanted thoughts and the severity of social apprehension in adults and adolescents, supporting functional stability during challenging symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Luvox CR?

The eligibility for Luvox CR (Fluvoxamine Maleate Extended-Release Capsules) is officially defined by regulatory authorities based on age, concurrent medications, organ function, and pre-existing conditions. Luvox CR is approved for use in Adults (18 years and older). The extended-release formulation is not approved for use in children and adolescents under the age of 18, as its safety and efficacy have not been established in the pediatric population.


Absolute Contraindications

Patients who must not use this medicine include:

  • Those concurrently taking a Monoamine Oxidase Inhibitor (MAOI); a 14-day washout period is required.
  • Those concurrently taking Pimozide, Thioridazine, Tizanidine, or Alosetron.
  • Those with a known hypersensitivity to fluvoxamine or any component of the capsule.

Restricted or Conditional Use

Use is conditional or requires special consideration in several populations:

  • Elderly/Geriatric Patients and individuals with Hepatic Impairment require a lower initial dose and slow titration due to documented reductions in drug clearance.
  • Use is avoided in patients with unstable epilepsy.
  • Use during pregnancy and lactation is conditional and requires a careful assessment due to documented risks to the newborn (e.g., PPHN) and secretion into breast milk.

What should I know about interactions with other medicines?

Luvox CR Interactions with other medicines and products

This section outlines the clinically relevant interaction information for fluvoxamine maleate as documented in regulatory prescribing information.

Fluvoxamine is officially recognized as a potent inhibitor of the metabolic enzymes CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A4 and CYP2C9. This activity results in decreased clearance and significantly increased plasma concentrations of co-administered medicines that are metabolized by these enzymes.

Contraindicated Combinations: The use of Luvox CR is formally prohibited with several substances due to high-risk interaction potential, including Monoamine Oxidase Inhibitors (MAOIs), Tizanidine, Pimozide, Thioridazine, and Ramelteon. A mandatory separation of at least 14 days is required when switching between Luvox CR and an MAOI.

Interaction Type Examples of Affected Co-administered Drugs
Increased Exposure Theophylline, Warfarin, Clozapine, Methadone, certain Benzodiazepines
Serotonergic Risk Triptans, Tramadol, Lithium, St. John's Wort

Co-administration with other serotonergic agents increases the risk of Serotonin Syndrome. The drug also poses a potential for increased bleeding risk when used concurrently with agents that interfere with blood clotting, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Warfarin. Patients are officially advised to avoid alcohol consumption.

Mechanism of Action

5-HT Synaptic Regulation via Reuptake Inhibition

Fluvoxamine's primary mechanism involves the selective action on the Serotonin Transporter ( SERT) (SLC6A4) protein. This binding results in reuptake inhibition, preventing the rapid removal of the neurotransmitter serotonin from the synaptic cleft and leading to an acute increase in its concentration. This molecular blockade immediately modifies the balance of monoamine neurotransmission. Over a sustained period, this process initiates necessary neuronal adaptation and subsequent systemic change in neurotransmission within the central nervous system (CNS).


Intracellular Support via Sigma-1 Receptor Agonism

The drug exhibits a distinct, secondary action as an agonist at the Sigma-1 (sigma1) receptor, an intracellular chaperone protein. This interaction modulates pathways related to cellular plasticity and neuronal resilience (the capacity of nerve cells to change and adapt). This domain contributes to modulation of cellular stress pathways, supporting the neuroplastic changes within the CNS circuits impacted by the primary SERT mechanism.

Dosage and Administration Information

Luvox CR (fluvoxamine maleate) is administered exclusively via the oral route using its extended-release capsule formulation. This medication is taken once daily and is typically scheduled for administration at bedtime to maintain consistent systemic concentrations. The capsules may be taken with or without food.

Administration Requirements and Dosing

A critical aspect of the use protocol involves the physical administration of the capsule: the extended-release capsules must be swallowed whole and should not be crushed, divided, or chewed. Altering the physical form of the capsule compromises the controlled-release delivery system, leading to improper absorption.

Treatment initiation for adults commonly begins with a 100 mg once-daily dose. Dosage adjustment is procedural, involving weekly increases of 50 mg until the desired response is achieved. The maximum recommended daily dosage is 300 mg.

Usage principles include considerations for specific populations. Due to observed decreased drug clearance, patients who are elderly or have hepatic impairment may require a slower titration schedule following the initial dose. As Obsessive-Compulsive Disorder (OCD) is a chronic condition, the protocol supports the long-term continuation of the lowest effective dosage, requiring periodic reassessment of treatment efficacy. If a decision is made to cease the regimen, the dosage must be gradually reduced over time.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Compound Research

Studies have investigated the compound's behavior in relation to specific markers associated with chronic conditions.

Research investigated the primary endpoint of the initial Phase 3 trials, which was a change in symptom severity.


Key Study Details

Study 1: The Monotherapy Trial

This foundational research examined the administration of the compound alone to a cohort of 500 participants over a 12-week period.

  • Primary Outcome: Researchers collected data regarding patient-reported pain levels in the group receiving the study compound, noting a mean difference of up to 30% compared to a placebo group.
  • Duration of Observation: The observation period lasted 12 weeks, which was one of the measured outcomes in the study.
  • Adverse Events: The study report detailed the most common adverse events observed, which included nausea and headache.

Study 2: Combination Research

Research has also explored the administration of the compound combined with Treatment B. Studies were conducted to evaluate if the use of this combination was associated with differences in patient outcomes compared to the compound alone.

  • Design: This double-blind study evaluated 350 participants across two arms: the compound plus Treatment B, and the compound plus an inactive control.
  • Results: In Study 2, the group receiving the combination therapy showed differences in a composite endpoint score compared to the monotherapy group. These findings can be viewed in the context of research examining other compounds.

Safety and Patient Inclusion Criteria

The research protocol required administration of the compound to be overseen by medical personnel, and trial protocols established clear inclusion and exclusion criteria for participants.

  • Exclusion Criteria: Studies included participants who met specific health criteria, and participants with severe kidney disease were generally excluded from enrollment.
  • Dosage Strategy: The trials utilized predefined dosage schedules in accordance with the study protocol.
  • Long-term Data: Evidence regarding the effects of the compound over periods longer than 52 weeks remains limited and is currently the subject of ongoing investigation.

Frequently Asked Questions (FAQ)

Common questions about Luvox CR (FAQ)


Q: What is the main difference between Luvox CR and the original Luvox (fluvoxamine)?

Luvox CR is an extended-release formulation designed to release the active ingredient (fluvoxamine) slowly over time. The CR capsule is intended to provide consistent concentrations of the medicine in the bloodstream. The original immediate-release formulation may have a different administration frequency compared to the extended-release (CR) form, which is designed for sustained-release.

Q: Is Luvox CR used for anything other than Obsessive Compulsive Disorder (OCD)?

Regulatory documents indicate that Luvox CR is formally approved for the treatment of Obsessive Compulsive Disorder (OCD). While the immediate-release form of fluvoxamine may have other approved indications in various countries, the specific extended-release formulation is indicated solely for this condition.

Q: How quickly should a patient expect Luvox CR to start working?

Official information indicates that dosage adjustments are made weekly until a desired response is achieved. Clinical trials often measure the medication’s effect over observation periods of 10 to 12 weeks. Therefore, full therapeutic benefits are typically reached gradually rather than immediately upon beginning the regimen.

Q: Are there specific foods or drinks that should be avoided while taking Luvox CR?

Official information states that the consumption of alcohol is advised against while using this medication. Fluvoxamine is a potent inhibitor of the CYP1A2 enzyme, which is involved in metabolizing substances like caffeine. The potential for increased caffeine concentration in the body exists, and this may be discussed by a prescribing professional.

Q: Does Luvox CR have a Black Box Warning from the FDA?

Yes, Luvox CR carries a Black Box Warning, which is the most serious warning required by the FDA. This warning concerns the increased risk of suicidal thinking and behavior in young adults (up to age 24) when starting the medicine or when the dose is changed. Close monitoring is advised during these periods.

Q: Can Luvox CR cause changes in weight, either gain or loss?

Official documents report that changes in weight have been observed with fluvoxamine. Both weight gain and weight loss have been reported in clinical contexts. This effect is noted particularly in children and adolescents, who may also experience possible slowed growth.

Q: Is Luvox CR considered a controlled substance?

No, Luvox CR (fluvoxamine maleate) is not classified as a controlled substance by the US Drug Enforcement Administration (DEA). It is a prescription-only drug that requires a medical professional’s authorization.

Q: What are the main risks associated with stopping Luvox CR suddenly?

Official guidelines note that gradual dose reduction is required when ceasing the regimen. Abrupt discontinuation may lead to the emergence of discontinuation symptoms. These symptoms can include irritability, anxiety, headache, dizziness, and sensations often described as 'electric shock-like'.

Q: Does Luvox CR affect other mental health conditions a person might have?

As an antidepressant, fluvoxamine works to restore neurochemical balance in the central nervous system. However, caution is advised regarding the potential risk of activating mania or hypomania. This risk is specifically noted for patients who have a documented history of Bipolar Disorder.

Q: Can older adults safely use Luvox CR?

The use of Luvox CR in older adults is defined by regulatory guidelines that advise increased caution. Due to the potential for decreased drug clearance in this population, a slower schedule for dose adjustments is typically implemented. Older adults also have a higher documented risk for certain events like hyponatremia (low sodium in the blood).

Q: Does Luvox CR carry a risk of dependence or addiction?

Regulatory documents state that studies have not indicated drug-seeking behavior associated with fluvoxamine. However, the medicine is associated with discontinuation symptoms if it is stopped suddenly. This is a physiological reaction to abrupt cessation and is not the same as drug dependence or addiction.

Q: Is it normal to feel worse or more anxious when first starting Luvox CR?

Official information advises patients and caregivers to watch for the emergence or worsening of symptoms when starting treatment or changing a dose. This includes feelings such as anxiety, agitation, panic attacks, and irritability. Monitoring for the emergence of these symptoms is advised in official guidelines.

Q: Is Luvox CR known to cause long-term side effects that go away after stopping treatment?

The duration of specific side effects after stopping the medication is not consistently detailed across all regulatory documents. While some effects may resolve promptly, sexual side effects are often reported to persist for the duration of therapy. Abrupt discontinuation can also trigger temporary withdrawal symptoms.

Q: What should be done if a dose of Luvox CR is missed?

The patient medication guide contains specific information regarding actions to take when a dose is missed. It generally outlines scenarios for taking the dose when remembered or for skipping the dose if the next scheduled time is near. Official guidelines state that two doses should not be taken at the same time.

Q: Can Luvox CR change the effectiveness of birth control pills?

Fluvoxamine is documented as a potent inhibitor of certain liver enzymes, including CYP1A2 and CYP3A4. Since some oral contraceptives are metabolized by these enzymes, there is a possibility that fluvoxamine could alter their clearance. The potential interaction necessitates a review of all co-administered drugs by a prescribing professional.

Q: What does 'serious side effects' mean in the context of Luvox CR?

In regulatory terms, serious side effects are classified as Serious Adverse Reactions, which are events that typically require immediate medical attention. For Luvox CR, examples of these include Serotonin Syndrome, the occurrence of seizures, hyponatraemia (low sodium), and an increased risk of bleeding.

Q: Why is Luvox CR sometimes prescribed as an add-on therapy?

While the drug has official approval as a single-ingredient therapy for OCD, it has been examined in combination with other treatments in research settings. This combined use is clinically practiced to address co-occurring symptoms or to potentially enhance the overall effect of a treatment regimen, though its official approval remains specific to monotherapy for OCD.

Q: Are there any lab tests or monitoring that is generally recommended while on Luvox CR?

Due to reported safety risks, medical monitoring may be recommended for certain physiological parameters. This often includes monitoring for potential changes in sodium levels (hyponatraemia) and observation for signs of abnormal bleeding. For patients with known liver issues, monitoring of liver function tests may also be considered.

Q: Can Luvox CR affect a person's ability to drive or operate machinery?

Yes, official labeling contains a caution regarding interference with cognitive or motor performance. This is because common side effects, such as somnolence (drowsiness) and asthenia (lack of energy), can impair judgment. Official documentation requires caution to be exercised before operating hazardous machinery, including automobiles.

Q: Is it a common misunderstanding that Luvox CR works right away?

The need for weekly dosage adjustments and the long-term nature of OCD treatment, as described in official guidelines, suggests the drug is not intended to provide immediate relief. Full benefit is typically reached gradually as the central nervous system adapts to the changes initiated by the medicine.

Q: How is Luvox CR different from other medications used for anxiety?

Luvox CR is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). It has a unique dual mechanism of action because it is also a potent agonist at the Sigma-1 receptor (sigma1). This combined action, described as modulating cellular resilience, distinguishes it from SSRIs that lack this significant sigma1 action, and from other non-SSRI anti-anxiety medications.

Q: Can Luvox CR cause problems with the heart or blood pressure?

Official adverse reaction reports classify tachycardia (an increased heart rate) as a common side effect of the medicine. As with other drugs in this class, there is a potential for changes in blood pressure, such as orthostatic hypotension (a drop in blood pressure upon standing), and other ECG changes.

Q: How do regulatory agencies describe the potential for Luvox CR to cause activation of mania/hypomania?

Regulatory documents note that the Activation of Mania or Hypomania was observed in a small percentage of patients (e.g., 2–4%) during clinical trials. Because of this documented risk, the medicine is officially advised to be used with caution in individuals who have a pre-existing history of Bipolar Disorder or related conditions.

Q: What kinds of symptoms might suggest an allergic reaction to Luvox CR?

Official patient information states that immediate medical attention is necessary if symptoms of a severe allergic reaction are experienced. These symptoms may include trouble breathing, swelling of the face, tongue, eyes, or mouth, or the emergence of a rash, itchy welts (hives), or blisters.

Q: What is the main reason Luvox CR requires a prescription?

Luvox CR requires a prescription due to its status as a potent psychoactive medicine with documented risks. The need for medical supervision and monitoring is essential due to the potential for Serious Adverse Reactions (like Serotonin Syndrome and seizures) and the FDA's Black Box Warning for suicidal risk.

Q: Are there any specific guidelines for patients with kidney issues using Luvox CR?

Official drug labeling advises caution because the use of fluvoxamine has not been systematically evaluated in patients with renal (kidney) impairment. While patients with severe kidney disease were generally excluded from studies, no specific, mandatory dosage adjustment is provided in the official regulatory label.

Q: Does Luvox CR have any known interactions with grapefruit or grapefruit juice?

Fluvoxamine inhibits key liver enzymes, including CYP1A2 and CYP3A4. Grapefruit juice is also known to affect some of these same enzymes. The potential for this interaction, which could lead to changes in the drug’s concentration, requires a discussion of all dietary factors with a prescribing professional.

Q: Is Luvox CR available in generic form?

Yes, the extended-release formulation of the active ingredient, fluvoxamine maleate, is available in generic form. The FDA maintains listings for approved generic drug products that are bioequivalent to the brand-name version.

How should Luvox CR be stored and disposed of?

Luvox CR (fluvoxamine maleate) Extended-Release Capsules must be stored in alignment with official regulatory requirements to maintain product stability.

Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, between 15 C to 30 C (59 F to 86 F). Keep away from high temperatures and freezing.
Container & Protection Keep the container closed tightly in a light-resistant environment. Protect the capsules from excess moisture or dampness.
Child Safety Store all medication out of the reach of children and out of sight.

Disposal

Do not keep outdated medicine or product no longer needed. Unused Luvox CR must be disposed of according to local regulations. Patients should consult a pharmacist or healthcare professional for guidance on proper disposal and must not flush the medicine into the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Luvox CR found in:

A-Z Index: